Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research ...
Morgan Stanley assumed coverage of Cullinan Therapeutics (CGEM) with an Overweight rating and a price target of $35, down from $38. The firm ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Cullinan Therapeutics to post earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results